Serotonin 5-HT1A receptors and their interactions with adenosine A2A receptors in Parkinson's disease and dyskinesia. (15th March 2023)

• Record Type: Journal Article
• Authors: Pinna, Annalisa; Parekh, Pathik; Morelli, Micaela
• Is Part Of: Neuropharmacology. Volume 226(2023)
• Publication Date: 2023-03-15
• Subjects: Dopamine -- Clinical trials -- Receptor interaction -- Basal ganglia -- A2A receptors -- 5-HT1A receptors -- Parkinson's disease -- Dyskinesia -- MPTP -- zif-268; Neuropsychopharmacology -- Periodicals; Autonomic Agents -- Periodicals; Neuropsychopharmacologie -- Périodiques; Neuropsychopharmacology; Periodicals; Electronic journals; 615.78
• DOI: 10.1016/j.neuropharm.2023.109411
• Languages: English
• ISSNs: 0028-3908

Abstract

Abstract: The dopamine neuronal loss that characterizes Parkinson's Disease (PD) is associated to changes in neurotransmitters, such as serotonin and adenosine, which contribute to the symptomatology of PD and to the onset of dyskinetic movements associated to levodopa treatment. The present review describes the role played by serotonin 5-HT1A receptors and the adenosine A2A receptors on dyskinetic movements induced by chronic levodopa in PD. The focus is on preclinical and clinical results showing the interaction between serotonin 5-HT1A receptors and other receptors such as 5-HT1B receptors and adenosine A2A receptors. 5-HT1A/1B receptor agonists and A2A receptor antagonists, administered in combination, contrast dyskinetic movements induced by chronic levodopa without impairing motor behaviour, suggesting that this drug combination might be a useful therapeutic approach for counteracting the PD motor deficits and dyskinesia associated with chronic levodopa treatment. This article is part of the Special Issue on "The receptor-receptor interaction as a new target for therapy". Highlights: Serotonin act on dyskinesia associated to chronic levodopa treatment. Serotoninergic 5-HT1A R agonists reduced dyskinesia. Adenosine A2A R antagonists increase levodopa efficacy on motor deficits. 5-HT1A/1B R agonist plus A2A R antagonist contrast dyskinesia. 5-HT1A/1B R agonist plus A2A R antagonist do not affect motor activity.